GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00094107 | Liver | NAFLD | response to xenobiotic stimulus | 88/1882 | 462/18723 | 2.53e-09 | 4.11e-07 | 88 |
GO:00098957 | Liver | NAFLD | negative regulation of catabolic process | 65/1882 | 320/18723 | 2.50e-08 | 2.71e-06 | 65 |
GO:00072654 | Liver | NAFLD | Ras protein signal transduction | 66/1882 | 337/18723 | 8.43e-08 | 7.09e-06 | 66 |
GO:00313307 | Liver | NAFLD | negative regulation of cellular catabolic process | 55/1882 | 262/18723 | 9.35e-08 | 7.59e-06 | 55 |
GO:00160495 | Liver | NAFLD | cell growth | 85/1882 | 482/18723 | 1.75e-07 | 1.25e-05 | 85 |
GO:00510564 | Liver | NAFLD | regulation of small GTPase mediated signal transduction | 56/1882 | 302/18723 | 4.62e-06 | 1.75e-04 | 56 |
GO:00105065 | Liver | NAFLD | regulation of autophagy | 57/1882 | 317/18723 | 1.00e-05 | 3.18e-04 | 57 |
GO:00072664 | Liver | NAFLD | Rho protein signal transduction | 31/1882 | 137/18723 | 1.19e-05 | 3.67e-04 | 31 |
GO:00485884 | Liver | NAFLD | developmental cell growth | 45/1882 | 234/18723 | 1.50e-05 | 4.38e-04 | 45 |
GO:0035024 | Liver | NAFLD | negative regulation of Rho protein signal transduction | 10/1882 | 22/18723 | 2.13e-05 | 5.97e-04 | 10 |
GO:00458606 | Liver | NAFLD | positive regulation of protein kinase activity | 65/1882 | 386/18723 | 2.22e-05 | 6.13e-04 | 65 |
GO:00465783 | Liver | NAFLD | regulation of Ras protein signal transduction | 38/1882 | 189/18723 | 2.42e-05 | 6.61e-04 | 38 |
GO:00336747 | Liver | NAFLD | positive regulation of kinase activity | 74/1882 | 467/18723 | 5.16e-05 | 1.19e-03 | 74 |
GO:00510583 | Liver | NAFLD | negative regulation of small GTPase mediated signal transduction | 16/1882 | 56/18723 | 8.53e-05 | 1.72e-03 | 16 |
GO:00030182 | Liver | NAFLD | vascular process in circulatory system | 46/1882 | 263/18723 | 1.36e-04 | 2.58e-03 | 46 |
GO:00075687 | Liver | NAFLD | aging | 53/1882 | 339/18723 | 7.78e-04 | 9.77e-03 | 53 |
GO:00465802 | Liver | NAFLD | negative regulation of Ras protein signal transduction | 13/1882 | 49/18723 | 8.43e-04 | 1.03e-02 | 13 |
GO:00033001 | Liver | NAFLD | cardiac muscle hypertrophy | 20/1882 | 99/18723 | 1.80e-03 | 1.85e-02 | 20 |
GO:00350233 | Liver | NAFLD | regulation of Rho protein signal transduction | 18/1882 | 86/18723 | 1.98e-03 | 1.98e-02 | 18 |
GO:0014897 | Liver | NAFLD | striated muscle hypertrophy | 20/1882 | 102/18723 | 2.61e-03 | 2.41e-02 | 20 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ADRA1A | SNV | Missense_Mutation | novel | c.495N>C | p.Trp165Cys | p.W165C | P35348 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
ADRA1A | SNV | Missense_Mutation | rs558845106 | c.1180N>A | p.Val394Ile | p.V394I | P35348 | protein_coding | tolerated_low_confidence(0.14) | benign(0.003) | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ADRA1A | SNV | Missense_Mutation | | c.617N>A | p.Arg206His | p.R206H | P35348 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AR-A1AH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | | PD |
ADRA1A | SNV | Missense_Mutation | rs772047975 | c.310N>T | p.Ala104Ser | p.A104S | P35348 | protein_coding | tolerated(0.17) | probably_damaging(0.953) | TCGA-GI-A2C9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | | SD |
ADRA1A | SNV | Missense_Mutation | novel | c.592N>A | p.Ala198Thr | p.A198T | P35348 | protein_coding | tolerated(0.51) | benign(0.02) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
ADRA1A | insertion | Nonsense_Mutation | novel | c.1249_1250insATTTCTGTCCGTTTATATAGCACTTTATGTTTGTCAAAGTAATTG | p.Ser417delinsTyrPheCysProPheIleTerHisPheMetPheValLysValIleAla | p.S417delinsYFCPFI*HFMFVKVIA | P35348 | protein_coding | | | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
ADRA1A | SNV | Missense_Mutation | rs757286802 | c.694G>T | p.Val232Leu | p.V232L | P35348 | protein_coding | tolerated(0.46) | benign(0.267) | TCGA-C5-A1BN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
ADRA1A | SNV | Missense_Mutation | novel | c.1034N>A | p.Cys345Tyr | p.C345Y | P35348 | protein_coding | deleterious(0.02) | benign(0.248) | TCGA-C5-A902-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
ADRA1A | SNV | Missense_Mutation | | c.391N>T | p.Pro131Ser | p.P131S | P35348 | protein_coding | tolerated(0.32) | possibly_damaging(0.773) | TCGA-JW-A5VJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
ADRA1A | SNV | Missense_Mutation | novel | c.903N>G | p.Phe301Leu | p.F301L | P35348 | protein_coding | tolerated(1) | benign(0.001) | TCGA-MA-AA3Y-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
148 | ADRA1A | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 135650785 | OXYMETAZOLINE | |
148 | ADRA1A | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | antagonist | CHEMBL3559672 | RAUWOLFIA SERPENTINA | |
148 | ADRA1A | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | | BENZPHETAMINE | BENZPHETAMINE | |
148 | ADRA1A | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | | DAPIPRAZOLE | DAPIPRAZOLE | |
148 | ADRA1A | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | antagonist | 178103686 | ALFUZOSIN | |
148 | ADRA1A | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | | Alpha-adrenoreceptor antagonists | | |
148 | ADRA1A | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | antagonist | CHEMBL1558 | PRAZOSIN HYDROCHLORIDE | |
148 | ADRA1A | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | | ALFUZOSIN | ALFUZOSIN | |
148 | ADRA1A | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | CHEMBL1356607 | NOREPINEPHRINE BITARTRATE | |
148 | ADRA1A | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 178100463 | DABUZALGRON | |